logo
Share SHARE
FONT-SIZE Plus   Neg

Misys Q3 Revenue Slips 12% - Quick Facts

Misys Plc (MSY.L, MUSJF.PK) reported a 12% drop in its third-quarter revenue to 89 million pounds from 100 million pounds in the prior-year period, on a pro-forma constant currency basis. Quarterly order intake was down by 18% to 52 million pounds from 63 million pounds a year ago. For comparative purposes, last year results are adjusted by the retranslation of results at current year exchange rates and by the addition of results from Sophis before its acquisition, at current year exchange rates, Misys added.

The company's Acting Chief Executive Tom Kilroy said, "Our third quarter results were impacted predominantly by the cautious approach adopted by customers whilst discussions were taking place about the future ownership of Misys, and also by continued challenging conditions in financial markets. However, we are confident that sales are being delayed rather than cancelled."

In light of the offer for the company announced today, Misys is withdrawing its previous medium-term revenue growth and operating profit margin targets as last announced on January 26, 2012 with the Misys results for the six months ending November 2011. The company anticipates that it is not possible to report on the profit forecast as there is too much uncertainty in the current market environment over the next 2 years and hence the profit forecast is being withdrawn and should not be relied upon.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Seafood lovers must now be prepared to dole out more cash than before for salmon. The price of salmon has surged globally and is now at historic highs amid acute outbreaks of sea lice. According to data from the Nasdaq Salmon Index, the price of salmon has risen by more than 15 percent in the last three months. Health-food restaurant chain Freshii Inc. has increased the price range for its initial public offering in Canada. Freshii has raised the price range for its IPO to C$10 to C$11.50 per share from the prior range of C$8.50 to C$10.0 per share, BNN reported. Drug major Johnson & Johnson Tuesday said it expects higher earnings and sales for its fiscal 2017, which are below market estimates. The company also reported solid fourth-quarter results, with adjusted earnings above market estimates, while sales missed their view, despite a growth. In pre-market activity on the NYSE, Johnson & Johnson shares were losing 1.68 percent.
comments powered by Disqus
Follow RTT